Carregant...
Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
The CD19 marker is expressed on the surface of normal and malignant immature or mature B-cells. On the other hand, immunotherapy involving T-cells is a promising modality of treatment for many neoplastic diseases including leukemias and lymphomas. The CD19/CD3-bispecific T-cell-engaging (BiTE(®)) mo...
Guardat en:
| Publicat a: | Onco Targets Ther |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4485855/ https://ncbi.nlm.nih.gov/pubmed/26170691 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S70524 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|